Mehtap Aydin
Overview
Explore the profile of Mehtap Aydin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basaran S, Simsek-Yavuz S, Saricaoglu M, Aydin M, Aygun G, Azap A, et al.
Anatol J Cardiol
. 2025 Mar;
29(3):111-117.
PMID: 40032639
Endocarditis is the most common cause of death from brucellosis. The information used to guide the management of cases with Brucella endocarditis has relied on case reports/series. Risk factors related...
2.
Altunal L, Aydin M, Ozel A, Cam G
Infect Dis Clin Microbiol
. 2024 Apr;
4(2):116-121.
PMID: 38633336
Objective: Interleukin-6 inhibitor Tocilizumab (TCZ) is effective to prevent the mortality of severe COVID-19 by suppressing the cytokine storm, however, its appropriate use needs to be detailed. We aimed to...
3.
Guclu K, Geyiktepe-Guclu C, Bayramlar O, Tuncer G, Aydin M
Rev Assoc Med Bras (1992)
. 2024 Mar;
70(1):e20230671.
PMID: 38511750
Objective: The aim of this study was to compare the clinical effects of the addition of anakinra to high-dose steroid therapy in COVID-19 patients with macrophage activation syndrome. Methods: This...
4.
Ekiz Iscanli I, Aydin M, Saylan B
J Infect Dev Ctries
. 2023 Nov;
17(10):1387-1393.
PMID: 37956367
Introduction: COVID-19 and secondary infections developing during COVID-19 follow-up are one of the most important causes of morbidity and mortality in intensive care units (ICU). In this study, we aimed...
5.
Ates I, Batirel A, Aydin M, Karadag F, Erden A, Kucuksahin O, et al.
Vaccines (Basel)
. 2023 Jul;
11(7).
PMID: 37515050
The immunogenicity of vaccines decreases over time, causing a need for booster doses. This study aimed to present the long-term (Day 84) immunogenicity results of the double-blind, randomized, controlled, phase...
6.
Isler B, Vatansever C, Ozer B, Cinar G, Aslan A, Falconer C, et al.
Infect Dis (Lond)
. 2023 Jul;
55(9):607-613.
PMID: 37391868
Background: Cefiderocol is generally active against carbapenem-resistant spp. (CRK) with higher MICs against metallo-beta-lactamase producers. There is a variation in cefiderocol interpretive criteria determined by EUCAST and CLSI. Our objective...
7.
Basaran M, Hazar M, Aydin M, Uzug G, Ozdogan I, Pala E, et al.
Toxics
. 2023 Apr;
11(4).
PMID: 37112613
Coronavirus disease 2019 (COVID-19) has posed a great threat to public health and has caused concern due to its fatal consequences over the last few years. Most people with COVID-19...
8.
Altunal L, Caglayik D, Ozel A, Tigen E, Sili U, Erturk Sengel B, et al.
AIDS Patient Care STDS
. 2023 Feb;
37(3):138-145.
PMID: 36812461
People living with human immunodeficiency virus (PLWH), with the availability of modern antiretroviral drugs, have multiple comorbidities, which increase the risk of polypharmacy and potential drug-drug interactions (PDDIs). This is...
9.
Isler B, Falconer C, Vatansever C, Ozer B, Cinar G, Aslan A, et al.
J Med Microbiol
. 2023 Feb;
71(12).
PMID: 36748503
Aminoglycosides are used for the treatment of carbapenemase-producing (CPK) infections. 16S rRNA methyltransferases (RMTs) confer resistance to all aminoglycosides and are often cocarried with NDM. There is a dart of...
10.
Omma A, Batirel A, Aydin M, Karadag F, Erden A, Kucuksahin O, et al.
Hum Vaccin Immunother
. 2022 Oct;
18(6):2122503.
PMID: 36315843
Protective neutralizing antibody titers reduce in time after COVID-19 vaccinations, as in individuals who have had COVID-19. This study aimed to evaluate the safety and immunogenicity of CoronaVac and TURKOVAC...